| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CUE | Common Stock | Purchase | $528,000 | +150,000 | +20% | $3.52 | 885,000 | 23 May 2022 | See footnote | F1, F2 |
| transaction | CUE | Common Stock | Purchase | $183,700 | +55,000 | +6.2% | $3.34 | 940,000 | 24 May 2022 | See footnote | F2, F3 |
| holding | CUE | Common Stock | 165,000 | 23 May 2022 | Direct | ||||||
| holding | CUE | Common Stock | 8,867 | 23 May 2022 | By Spouse |
| Id | Content |
|---|---|
| F1 | The reported shares were purchased in the open market in multiple transactions at prices ranging from $3.31 to $3.62. The price reported in Column 4 is a weighted average price. |
| F2 | The reported shares were purchased, and are owned, directly by Bios Special Opportunity Fund, LP. Aaron Fletcher is the manager of Bios Advisors GP, LLC, the general partner of Bios Capital Management, L.P., the general partner of Bios Equity SOF I, LP, the general partner of Bios Special Opportunity Fund, LP. Dr. Fletcher disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Dr. Fletcher is the beneficial owner of any securities covered by this Form 4. |
| F3 | The reported shares were purchased in the open market in multiple transactions at prices ranging from $3.21 to $3.52. The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Cue Biopharma, Inc., any stockholder of Cue Biopharma, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnotes (1) and (3). |